Use of florbetapir-PET for imaging beta-amyloid pathology
| Autor: | Christopher M, Clark, Julie A, Schneider, Barry J, Bedell, Thomas G, Beach, Warren B, Bilker, Mark A, Mintun, Michael J, Pontecorvo, Franz, Hefti, Alan P, Carpenter, Matthew L, Flitter, Michael J, Krautkramer, Hank F, Kung, R Edward, Coleman, P Murali, Doraiswamy, Adam S, Fleisher, Marwan N, Sabbagh, Carl H, Sadowsky, Eric P, Reiman, P Eric M, Reiman, Simone P, Zehntner, Daniel M, Skovronsky |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty Pathology Endpoint Determination Context (language use) Autopsy Article Alzheimer Disease medicine Medical imaging Dementia Humans False Positive Reactions Prospective Studies Drug Approval Florbetaben Aged Observer Variation Brain Chemistry Amyloid beta-Peptides Aniline Compounds medicine.diagnostic_test United States Food and Drug Administration business.industry Brain Anatomical pathology General Medicine Middle Aged medicine.disease Immunohistochemistry United States Positron emission tomography Positron-Emission Tomography Ethylene Glycols Female Alzheimer's disease Radiopharmaceuticals business Nuclear medicine |
| Zdroj: | JAMA. 305(3) |
| ISSN: | 1538-3598 |
| Popis: | CONTEXT: The ability to identify and quantify brain β-amyloid could increase the accuracy of a clinical diagnosis of Alzheimer disease. OBJECTIVE: To determine if florbetapir F 18 positron emission tomographic (PET) imaging performed during life accurately predicts the presence of β-amyloid in the brain at autopsy. DESIGN, SETTING, AND PARTICIPANTS: Prospective clinical evaluation conducted February 2009 through March 2010 of florbetapir-PET imaging performed on 35 patients from hospice, long-term care, and community health care facilities near the end of their lives (6 patients to establish the protocol and 29 to validate) compared with immunohistochemistry and silver stain measures of brain β-amyloid after their death used as the reference standard. PET images were also obtained in 74 young individuals (18–50 years) presumed free of brain amyloid to better understand the frequency of a false-positive interpretation of a florbetapir-PET image. MAIN OUTCOME MEASURES: Correlation of florbetapir-PET image interpretation (based on the median of 3 nuclear medicine physicians’ ratings) and semiautomated quantification of cortical retention with postmortem β-amyloid burden, neuritic amyloid plaque density, and neuropathological diagnosis of Alzheimer disease in the first 35 participants autopsied (out of 152 individuals enrolled in the PET pathological correlation study). RESULTS: Florbetapir-PET imaging was performed a mean of 99 days (range, 1–377 days) before death for the 29 individuals in the primary analysis cohort. Fifteen of the 29 individuals (51.7%) met pathological criteria for Alzheimer disease. Both visual interpretation of the florbetapir-PET images and mean quantitative estimates of cortical uptake were correlated with presence and quantity of β-amyloid pathology at autopsy as measured by immunohistochemistry (Bonferroni ρ, 0.78 [95% confidence interval, 0.58–0.89]; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|